VP Strategy, COTA (Clinical Outcomes Tracking and Analysis)
COTA enables precision medicine for cancer patients through its patented classification system that transforms prognostically significant variables into a digital code, precisely categorizing patient factors, their diseases and intended therapy to measure and improve treatment outcomes. COTA helps the medical community identify variances in care, benchmark quality, and discover the most effective treatments based on precise patient cohorts.
COTA was founded by oncologists and is equity backed by Horizon Blue Cross Blue Shield of New Jersey, Hackensack University Medical Center, Novartis, Celgene, and Foundation Medicine.
Matt is an Arabic track graduate of 2011. He has worked in the Pentagon and McKinsey.